Mylan Laboratories Inc. Announces Executive Appointments
Posted on: Tuesday, 25 October 2005, 21:01 CDT
PITTSBURGH, Oct. 25 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. and its generic subsidiary Mylan Pharmaceuticals Inc. today announced four executive appointments.
John Deiriggi was appointed to the new position of Chief Operating Officer at Mylan Pharmaceuticals. Mr. Deiriggi is a 19-year veteran of Mylan, serving most recently as Vice President of Generic Business Development. Mr. Deiriggi has a wide variety of experience at Mylan, in areas including strategic planning, research and development, quality control and purchasing.
Daniel Caron was promoted to take over Mr. Deiriggi's former position as Vice President of Generic Business Development. Mr. Caron joined Mylan Technologies Inc. as Chief Financial Officer in 2001, and was promoted to Executive Director of Corporate Administration at Mylan Laboratories in 2002. Earlier in his career he served as Executive Vice President of Finance and Chief Financial Officer of Copley Pharmaceuticals.
Gary Sphar was appointed to the new position of Executive Vice President and Chief Financial Officer of Mylan Pharmaceuticals. Mr. Sphar has been employed in various accounting and finance positions by Mylan since 1992, including most recently as Vice President and Corporate Controller of Mylan Laboratories and Vice President-Finance of Mylan Pharmaceuticals.
Brian Roman was appointed to the new position of Vice President and General Counsel at Mylan Pharmaceuticals. Mr. Roman joined Mylan in 2003 as Litigation Counsel, responsible for overseeing and directing all litigation involving Mylan Laboratories and its subsidiaries. Prior to joining Mylan, Mr. Roman was a partner at DKW Law Group, a Pittsburgh-based law firm.
Hal Korman, president of Mylan Pharmaceuticals, commented: "Since taking over as President earlier this year, I have closely evaluated our organization to determine the proper structure that will allow us to further maximize on the increasing generic industry opportunities. These senior executives are proven leaders and Mylan Pharmaceuticals will benefit from their deep industry knowledge and experience in these critical roles."
About Mylan Laboratories
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc. that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.
Mylan Laboratories Inc.
CONTACT: Media, Patrick Fitzgerald, +1-724-514-1800, or Investors, KrisKing, +1-724-514-1800, both of Mylan Laboratories Inc.
Web site: http://www.mylan.com/
Source: PRNewswire-FirstCall
Related Articles
- Healthplace America Names Todd Roscoe to New Position of Chief Managed Care Officer
- Duke Energy Appoints De May as Senior Vice President, Treasurer and Chief Risk Officer
- Noven Names Joel Lippman, M.D. As Vice President - Clinical Development & Chief Medical Officer
- Eric Lofgren Joins Burnham Institute for Medical Research As Vice President, Finance and Chief Financial Officer
- Elixir Pharmaceuticals Names Paul M. Martha, M.D. As Chief Medical Officer
- Westwood One Continues Forward Momentum in Digital Media With the Appointment of Gary Krantz to Newly Created Position of Chief Digital Media Officer
- NitroMed Promotes Michael Sabolinski, M.D. To the Position of Chief Medical Officer
- Northwest Airlines Names Anna Schaefer Vice President - Finance and Chief Accounting Officer
- Mylan Laboratories Inc. Reports Positive Development From FDA Advisory Committee Vote on EMSAM(R)
 |
 |
User Comments (0)
RSS Feeds